GlassScriptPhysician profile
Amanda Cantu
NPI 1093102923
$9,052.22
in general payments reported to CMS, 2019-2025
41 companies · $2,787 in 2025
The $2,787 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $761 · 2021: $1,007 · 2022: $1,089 · 2023: $982 · 2024: $1,846 · 2025: $2,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,568 · Entertainment: $25.92 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,567.61 |
| Entertainment | $25.92 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,315.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Ascensia Diabetes Care US INC. | $761.34 | 2024-2025 | |
| Dexcom, INC. | $607.69 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $598.67 | 2021-2025 | Tepezza, Evenity, Repatha |
| Corcept Therapeutics | $572.04 | 2019-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $533.49 | 2019-2025 | |
| Lilly USA, LLC | $326.12 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Insulet Corporation | $316.05 | 2020-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $305.57 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Radius Health, INC. | $293.65 | 2020-2025 | Tymlos |
| Mannkind Corporation | $197.19 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $190.39 | 2025 | Isturisa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.08 | 2020-2025 | Jardiance |
| Neurocrine Biosciences, INC. | $162.74 | 2024-2025 | Crenessity |
| Intuity Medical INC | $154.91 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $136.06 | 2021-2025 | |
| Abbott Laboratories | $133.23 | 2021-2025 | Freestyle Libre |
| Antares Pharma, INC. | $123.14 | 2021-2023 | Tlando, Nocdurna, Xyosted |
| Cequr Corporation | $117.68 | 2023-2025 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $110.19 | 2023-2025 | |
| Tandem Diabetes Care, INC. | $106.56 | 2019-2022 | |
| Shire North American Group INC | $106.53 | 2019 | |
| Amarin Pharma, INC. | $90.38 | 2020-2022 | |
| Astellas Pharma US INC | $78.84 | 2024-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $66.17 | 2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $51.78 | 2019-2025 | Strensiq |
| Madrigal Pharmaceuticals | $51.75 | 2025 | Rezdiffra |
| Horizon Therapeutics Plc | $49.25 | 2020-2023 | Tepezza |
| Averitas Pharma INC. | $47.62 | 2024-2025 | Qutenza |
| Abbvie INC. | $39.66 | 2025 | |
| Beta Bionics, INC. | $32.77 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Nevro Corp. | $32.58 | 2024 | Senza |
| Kyowa Kirin, INC. | $28.35 | 2025 | |
| Soleno Therapeutics, INC. | $22.19 | 2025 | Vykat Xr |
| Chiesi USA, INC. | $21.60 | 2024 | Mycapssa |
| Merck Sharp & Dohme LLC | $19.30 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $16.75 | 2024 | |
| Medtronic Minimed, INC. | $14.07 | 2019 | |
| Tolmar, INC. | $14.06 | 2025 | Jatenzo |
| Astrazeneca Pharmaceuticals LP | $13.82 | 2021 | |
| Ferring Pharmaceuticals INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Cantu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.